Literature DB >> 15210553

Vessel density, proliferation, and immunolocalization of vascular endothelial growth factor in juvenile nasopharyngeal angiofibromas.

Jürgen Brieger1, Magorzata Wierzbicka, Maxim Sokolov, Yehudah Roth, Witold Szyfter, Wolf J Mann.   

Abstract

BACKGROUND: Juvenile nasopharyngeal angiofibroma (JNA) is a rare, highly vascularized neoplasm of the nasopharynx that affects boys and young men. The underlying dysregulated molecular mechanisms remain unclear. The participation of angiogenic growth factors has been suggested, but few studies have been published.
OBJECTIVES: To evaluate the expression and localization of vascular endothelial growth factor (VEGF), proliferating cells, and vessel density in JNA. STUDY
DESIGN: Immunohistochemical examination of 10 consecutive JNAs (8 primary tumors and 2 recurrent tumors).
METHODS: Paraffin-embedded and cryopreserved JNA samples were included. VEGF-, CD31-, and Ki67-specific antibodies were applied and visualized using light microscopy. Vascularization was determined by counting CD31-positive vessels. Proliferating and VEGF-expressing vessels as well as stromal cells were quantified by the same method. Patients' age at the time of surgery and tumor stage were correlated with the immunohistochemical data.
RESULTS: All tumors were heavily vascularized, but major differences were noted between the samples. About half of the vessels were proliferating (Ki67 positive) and half of the Ki67-positive cells were also VEGF positive. The tumor stroma was VEGF positive in 8 of 10 samples and proliferating in 5 of these 8. The 5 samples with both VEGF- and Ki67-positive stroma showed high vessel densities. No correlation was observed between age or tumor stage and vessel density, VEGF expression, or Ki67 expression.
CONCLUSIONS: In JNA, VEGF is frequently expressed by stromal cells and vessels and is associated with proliferation and increased vessel density. We suggest the promotion of vascularization by VEGF, but the involvement of androgens in JNA angiogenesis still needs to be analyzed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210553     DOI: 10.1001/archotol.130.6.727

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  14 in total

1.  Immunohistochemical analysis of growth mechanisms in juvenile nasopharyngeal angiofibroma.

Authors:  Robert Schuon; Jürgen Brieger; Ulf R Heinrich; Yeduha Roth; Witold Szyfter; Wolf J Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-12-20       Impact factor: 2.503

2.  Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.

Authors:  Tran Le; Jacob New; Joel W Jones; Shireen Usman; Sreeya Yalamanchali; Ossama Tawfik; Larry Hoover; Dan E Bruegger; Sufi Mary Thomas
Journal:  Int Forum Allergy Rhinol       Date:  2017-07-14       Impact factor: 3.858

3.  Epstein-Barr virus and human herpes virus-8 are not associated with juvenile nasopharyngeal angiofibroma.

Authors:  Román Carlos; Lester D R Thompson; Ana Carolina Netto; Luiz Gustavo Garcia Santos Pimenta; Jeane de Fátima Correia-Silva; Carolina Cavaliéri Gomes; Ricardo Santiago Gomez
Journal:  Head Neck Pathol       Date:  2008-07-01

4.  Markers of vascular differentiation, proliferation and tissue remodeling in juvenile nasopharyngeal angiofibromas.

Authors:  Suely Nonogaki; Heloisa G A Campos; Ossamu Butugan; Fernando A Soares; Flávia Regina Rotea Mangone; Humberto Torloni; M Mitzi Brentani
Journal:  Exp Ther Med       Date:  2010-08-26       Impact factor: 2.447

5.  Stem cell-related proteins C-KIT, C-MYC and BMI-1 in juvenile nasopharyngeal angiofibroma--do they have a role?

Authors:  Suvi Renkonen; Valtteri Häyry; Päivi Heikkilä; Ilmo Leivo; Caj Haglund; Antti A Mäkitie; Jaana Hagström
Journal:  Virchows Arch       Date:  2010-11-27       Impact factor: 4.064

6.  Clinical correlation of molecular (VEGF, FGF, PDGF, c-Myc, c-Kit, Ras, p53) expression in juvenile nasopharyngeal angiofibroma.

Authors:  Anupam Mishra; Subhash Chandra Mishra; Ashoak Mani Tripathi; Amita Pandey
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-31       Impact factor: 2.503

7.  The changing surgical management of juvenile nasopharyngeal angiofibroma.

Authors:  Suvi Renkonen; Jaana Hagström; Jyrki Vuola; Mika Niemelä; Matti Porras; Sanna-Maria Kivivuori; Ilmo Leivo; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-17       Impact factor: 2.503

8.  Mast cells and T-lymphocytes in juvenile angiofibromas.

Authors:  Olaf Wendler; Renate Schäfer; Bernhard Schick
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-20       Impact factor: 2.503

9.  Anti-human vascular endothelial growth factor (VEGF) antibody selection for immunohistochemical staining of proliferating blood vessels.

Authors:  Chris M van der Loos; Lorine B Meijer-Jorna; Marloes E C Broekmans; Hanneke P H M Ploegmakers; Peter Teeling; Onno J de Boer; Allard C van der Wal
Journal:  J Histochem Cytochem       Date:  2010-02       Impact factor: 2.479

10.  Differential Gene Expression and Pathway Analysis in Juvenile Nasopharyngeal Angiofibroma Using RNA Sequencing.

Authors:  Joel W Jones; Shireen Usman; Jacob New; Andrew Holcomb; Sumedha Gunewardena; Ossama Tawfik; Larry Hoover; Daniel Bruegger; Sufi Mary Thomas
Journal:  Otolaryngol Head Neck Surg       Date:  2018-04-10       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.